{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T20:47:42Z","timestamp":1789850862241,"version":"4.0.1"},"reference-count":26,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,5,1]],"date-time":"2017-05-01T00:00:00Z","timestamp":1493596800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","nucmedbio.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Nuclear Medicine and Biology"],"published-print":{"date-parts":[[2017,5]]},"DOI":"10.1016\/j.nucmedbio.2017.01.006","type":"journal-article","created":{"date-parts":[[2017,1,17]],"date-time":"2017-01-17T02:48:19Z","timestamp":1484621299000},"page":"16-25","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"special_numbering":"C","title":["Redesign of negatively charged 111 In-DTPA-octreotide derivative to reduce renal radioactivity"],"prefix":"10.1016","volume":"48","author":[{"given":"Nobuhiro","family":"Oshima","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Akizawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hidekazu","family":"Kawashima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Songji","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-ichi","family":"Nishijima","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoji","family":"Kitamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasushi","family":"Arano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Kuge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazue","family":"Ohkura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0005","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s12022-013-9295-2","article-title":"Neuroendocrine tumors of the pancreas: current concepts and controversies","volume":"25","author":"Reid","year":"2014","journal-title":"Endocr Pathol"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0010","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/S0167-0115(99)00121-4","article-title":"Somatostatin receptor gene expression in neuroblastoma","volume":"88","author":"Albers","year":"2000","journal-title":"Regul Pept"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0015","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1002\/1096-911X(20010101)36:1<224::AID-MPO1054>3.0.CO;2-#","article-title":"Somatostatin receptor type 2 gene expression in neuroblastoma, measured by competitive RT-PCR, is related to patient survival and to somatostatin receptor imaging by indium-111-pentetreotide","volume":"36","author":"Orlando","year":"2001","journal-title":"Med Pediatr Oncol"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.2217\/ije.15.5","article-title":"Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors: current state and future perspective","volume":"2","author":"Baum","year":"2015","journal-title":"Int J Endocr Oncol"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0025","doi-asserted-by":"crossref","first-page":"448","DOI":"10.7150\/thno.3931","article-title":"Molecular imaging radiotherapy: theranostics for personalized patient Management of Neuroendocrine Tumors (NETs)","volume":"2","author":"\u00d6berg","year":"2012","journal-title":"Theranostics"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0030","first-page":"347","article-title":"Peptide receptor radionuclide therapy (PRRT) of neuroendocrine tumors with somatostatin analogues","volume":"14","author":"Bodei","year":"2010","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0035","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1016\/0024-3205(91)90053-E","article-title":"In vivo application of [111In-DTPA-d-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats","volume":"49","author":"Bakker","year":"1991","journal-title":"Life Sci"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0040","first-page":"652","article-title":"Somatostatin receptor scintigraphy with indium-111-DTPA-d-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide","volume":"33","author":"Krenning","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0045","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1007\/s002590050476","article-title":"Yttrium-90 DOTATOC: first clinical results","volume":"26","author":"Otte","year":"1999","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0050","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1093\/annonc\/mdp372","article-title":"Efficacy of radionuclide treatment DOTATATE Y-90 in patients with progressive metastatic gastroenteropancreatic neuroendocrine carcinomas (GEP-NETs): a phase II study","volume":"21","author":"Cwikla","year":"2010","journal-title":"Ann Oncol"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0055","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.addr.2008.04.005","article-title":"Renal uptake and metabolism of radiopharmaceuticals derived from peptides and proteins","volume":"60","author":"Akizawa","year":"2008","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0060","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00259-002-0982-3","article-title":"Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine","volume":"30","author":"Rolleman","year":"2003","journal-title":"Eur J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0065","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1038\/bjc.1993.266","article-title":"Amino acid infusion blocks renal tubular uptake of an indium-labelled somatostatin analogue","volume":"67","author":"Hammond","year":"1993","journal-title":"Br J Cancer"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0070","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/S0969-8051(01)00241-4","article-title":"Effect of molecular charges on renal uptake of 111In-DTPA-conjugated peptides","volume":"28","author":"Akizawa","year":"2001","journal-title":"Nucl Med Biol"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0075","doi-asserted-by":"crossref","first-page":"2226","DOI":"10.1248\/bpb.30.2226","article-title":"Effect of carboxyl-group of d-glutamic acid or gamma-carboxy-d-glutamic acid as N-terminal amino acid of 111In-diethylenetriaminepentaacetic acid-octreotide on accumulation of radioactivity in kidney","volume":"30","author":"Akizawa","year":"2007","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0080","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1248\/bpb.27.271","article-title":"Effect of carboxylation of N-terminal phenylalanine of 111In-DTPA (diethylenetriaminepentaacetic acid)-octreotide on accumulation of radioactivity in kidney","volume":"27","author":"Akizawa","year":"2004","journal-title":"Biol Pharm Bull"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0085","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1016\/j.bmc.2013.12.063","article-title":"Design, synthesis and biological evaluation of negatively charged 111In-DTPA-octreotide derivatives","volume":"22","author":"Oshima","year":"2014","journal-title":"Bioorg Med Chem"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0090","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1021\/bc970158h","article-title":"Identification of the soluble in vivo metabolites of indium-111-diethylenetriaminepentaacetic acid-d-Phe1-octreotide","volume":"9","author":"Bass","year":"1998","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0095","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1021\/bc9702258","article-title":"Renal metabolism of 111In-DTPA-d-Phe1-octreotide in vivo","volume":"9","author":"Akizawa","year":"1998","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0100","doi-asserted-by":"crossref","first-page":"3451","DOI":"10.1021\/jm950949+","article-title":"Reassessment of diethylenetriaminepentaacetic acid (DTPA) as a chelating agent for indium-111 labeling of polypeptides using a newly synthesized monoreactive DTPA derivative","volume":"39","author":"Arano","year":"1996","journal-title":"J Med Chem"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0105","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1021\/bc970023b","article-title":"Conventional and high-yield synthesis of DTPA-conjugated peptides: application of a monoreactive DTPA to DTPA-d-Phe1-octreotide synthesis","volume":"8","author":"Arano","year":"1997","journal-title":"Bioconjug Chem"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0110","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/0003-2697(70)90146-6","article-title":"Color test for detection of free terminal amino groups in the solid-phase synthesis of peptides","volume":"34","author":"Kaiser","year":"1970","journal-title":"Anal Biochem"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0115","first-page":"900","article-title":"Characterization of the two diastereomers of octreoscan-111, an In-111 labeled peptide for use in cancer imaging","volume":"33","author":"Albert","year":"1992","journal-title":"J Nucl Med"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0120","article-title":"Test No. 117: Partition Coefficient (n-octanol\/water), HPLC Method","author":"Scicchitano","year":"2017","journal-title":"Adopted by the Council on 23th November 2004."},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0125","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1016\/0889-1591(87)90019-5","article-title":"Distribution of somatostatin receptors on murine spleen and Peyer's patch T and B lymphocytes","volume":"1","author":"Scicchitano","year":"1987","journal-title":"Brain Behav Immun"},{"key":"10.1016\/j.nucmedbio.2017.01.006_bb0130","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1177\/002215540405200310","article-title":"Expression and distribution of somatostatin receptor subtypes in the pancreatic islets of mice and rats","volume":"52","author":"Ludvigsen","year":"2004","journal-title":"J Histochem Cytochem"}],"container-title":["Nuclear Medicine and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805116303559?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0969805116303559?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T22:24:37Z","timestamp":1536099877000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0969805116303559"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,5]]},"references-count":26,"alternative-id":["S0969805116303559"],"URL":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.01.006","relation":{},"ISSN":["0969-8051"],"issn-type":[{"value":"0969-8051","type":"print"}],"subject":[],"published":{"date-parts":[[2017,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Redesign of negatively charged 111In-DTPA-octreotide derivative to reduce renal radioactivity","name":"articletitle","label":"Article Title"},{"value":"Nuclear Medicine and Biology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.nucmedbio.2017.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}